368 related articles for article (PubMed ID: 30267354)
1. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
[TBL] [Abstract][Full Text] [Related]
3. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
5. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
6. Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference.
Kreutz J; Vroonen L; Cattin F; Petrossians P; Thiry A; Rostomyan L; Tshibanda L; Beckers A; Bonneville JF
Neuroradiology; 2015 Jul; 57(7):679-84. PubMed ID: 25845810
[TBL] [Abstract][Full Text] [Related]
7. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?
Alkabbani AG; Mon SY; Hatipoglu B; Kennedy L; Faiman C; Weil RJ; Hamrahian AH
Pituitary; 2014 Apr; 17(2):97-102. PubMed ID: 23468127
[TBL] [Abstract][Full Text] [Related]
8. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
9. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
10. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
12. Non-surgical management of cystic prolactinomas.
Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
[TBL] [Abstract][Full Text] [Related]
13. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
14. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
15. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
16. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
17. Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review.
Carija R; Vucina D
CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):1012-4. PubMed ID: 23244423
[TBL] [Abstract][Full Text] [Related]
18. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance.
Elenkova A; Genov N; Abadzhieva Z; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):201-5. PubMed ID: 23595795
[TBL] [Abstract][Full Text] [Related]
19. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients.
Salenave S; Ancelle D; Bahougne T; Raverot G; Kamenický P; Bouligand J; Guiochon-Mantel A; Linglart A; Souchon PF; Nicolino M; Young J; Borson-Chazot F; Delemer B; Chanson P
J Clin Endocrinol Metab; 2015 Mar; 100(3):1177-86. PubMed ID: 25532043
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]